Stockscreener 앱 받기
0.705
0.70%
-0.005
시간 외 거래:
.72
0.015
+2.13%
전일 마감가:
$0.71
열려 있는:
$0.69
하루 거래량:
9,558
Relative Volume:
0.19
시가총액:
$2.45M
수익:
$1.26M
순이익/손실:
$-8.55M
주가수익비율:
-0.0574
EPS:
-12.2724
순현금흐름:
$-6.38M
1주 성능:
-3.42%
1개월 성능:
-7.24%
6개월 성능:
-55.10%
1년 성능:
-79.54%
1일 변동 폭
$0.69
$0.7156
1주일 범위
$0.68
$0.7605
52주 변동 폭
$0.613
$6.18
Scinai Immunotherapeutics Ltd Adr Stock (SCNI) Company Profile
명칭
Scinai Immunotherapeutics Ltd Adr
전화
972-8-9302529
주소
JERUSALEM BIOPARK, 2ND FLOOR, JERUSALEM
Compare SCNI vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SCNI
Scinai Immunotherapeutics Ltd Adr
|
0.705 | 2.46M | 1.26M | -8.55M | -6.38M | -12.27 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Scinai Immunotherapeutics Ltd Adr 주식(SCNI)의 최신 뉴스
Scinai Immunotherapeutics Highlights Expanded CDMO Platform and Immunology Pipeline at BIO-Europe Spring 2026 - Finviz
Scinai Immunotherapeutics Receives Nasdaq Notification Regarding Minimum Bid Price - Finviz
Scinai Immunotherapeutics Receives Nasdaq Notification Regarding Minimum Bid Price - Benzinga
Scinai Signs Second Amendment to PinCell Option Agreement and Submits Revised 12 Million Non-Dilutive FENG Application to Advance PC111 Through Human Proof of Concept - Finviz
SUNation Energy Inc. (NASDAQ:SUNE) Short Interest Update - Defense World
Enerflex (NYSE:EFXT) Shares Gap Up Following Dividend Announcement - Defense World
Scinai receives expanded grant for robotic manufacturing system - Investing.com
Scinai Announces Expanded Israel Innovation Authority Support for Robotic Aseptic Fill & Finish Platform - Finviz
Scinai Announces Completion of Acquisition of Recipharm Israel Ltd. and Strategic Commercial Collaboration with Recipharm - Barchart
Scinai Immunotherapeutics (NASDAQ:SCNI) Shares Down 3.1% – Here’s Why - Defense World
Scinai Immunotherapeutics Reports Growth and Pipeline Progress - MSN
Scinai CEO Amir Reichman to Co-Lead Manufacturers Association Biopharma Manufacturing Roundtable at HealthIL - Finviz
Working capital per share of Scinai Immunotherapeutics Ltd. Sponsored ADR – MUN:2F5 - TradingView — Track All Markets
Coca-Cola HBC (OTCMKTS:CCHGY) Trading 3.7% Higher – Should You Buy? - Defense World
PCCW (OTCMKTS:PCWLF) Trading Down 7.9% – Here’s Why - Defense World
Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) Sees Large Drop in Short Interest - Defense World
Scinai Immunotherapeutics (NASDAQ:SCNI) Stock Price Down 1.3% – Should You Sell? - Defense World
Revenue per share of Scinai Immunotherapeutics Ltd. Sponsored ADR – BER:2F5 - TradingView — Track All Markets
Scinai Immunotherapeutics (NASDAQ:SCNI) Shares Up 3% – What’s Next? - Defense World
Scinai reports revenue growth as CDMO business expands By Investing.com - Investing.com India
Scinai reports revenue growth as CDMO business expands - Investing.com
Scinai Reports Nine-Month 2025 Results as CDMO Growth Continues and NanoAbs Pipeline Advances - Barchart.com
Revenue per share of Scinai Immunotherapeutics Ltd. Sponsored ADR – MUN:2F5 - TradingView
SCNI | Scinai Immunotherapeutics Ltd. ADR SEC Filings - MarketWatch
Scinai Immunotherapeutics schedules annual meeting for December 22 - Investing.com
Scinai Immunotherapeutics schedules annual meeting for December 22 By Investing.com - Investing.com South Africa
Cash per share of Scinai Immunotherapeutics Ltd. Sponsored ADR – BER:2F5 - TradingView
Scinai receives $246,000 grant to expand biotech manufacturing By Investing.com - Investing.com South Africa
Scinai receives $246,000 grant to expand biotech manufacturing - Investing.com
Scinai Reports Six-Month 2025 Financial Results Highlighting Continued CDMO Revenue Growth and Strengthened Balance Sheet - Finviz
Scinai’s PC111 antibody shows promise for pemphigus treatment - Investing.com
Scinai Immunotherapeutics (SCNI) FDA Approvals, PDUFA Dates & Drug Alerts 2025 - MarketBeat
Scinai Highlights Award-Winning Science Behind PC111 as Key Pincell Researcher Receives "Oscar of Italian Dermatology" - Finviz
Scinai Immunotherapeutics Receives Italian Government Clearance Under Golden Power Regulation for Potential Acquisition of Pincell S.r.l. - Finviz
Scinai Immunotherapeutics Faces Financial Challenges, Seeks Growth - TipRanks
Scinai Announces Annual Financial Results for 2024 - Finviz
Scinai Immunotherapeutics (NASDAQ: SCNI) Enters Option Agreement to Acquire Italian Biotech Pincell - The Globe and Mail
Scinai Immunotherapeutics (NASDAQ: SCNI) Expands CDMO Operations with New U.S. Subsidiary - The Globe and Mail
Scinai Immunotherapeutics (SCNI) Stock Forecast and Price Target 2025 - MarketBeat
Scinai Immunotherapeutics enacts reverse split to meet Nasdaq rules - Investing.com India
symbol__ Stock Quote Price and Forecast - CNN
Scinai Immunotherapeutics (SCNI) Short Interest & Short Float | Updated Mar 2026 - MarketBeat
Scinai Immunotherapeutics Ltd. Sponsored ADR Cash Flow – NASDAQ:SCNI - TradingView
Scinai Immunotherapeutics (SCNI) Institutional Ownership 2025 - MarketBeat
SCNI Stock Price and Chart — NASDAQ:SCNI - TradingView
Scinai Immunotherapeutics (SCNI) Stock Price, News & Analysis - MarketBeat
Scinai Immunotherapeutics Ltd Share Price ADR Each Representing 400 Ord Shares SPON - Hargreaves Lansdown
SCNIScinai Immunotherapeutics Ltd ADR Stock Price and Quote - Finviz
What is the current Price Target and Forecast for Scinai Immunotherapeutics Ltd. Sponsored ADR (SCNI) - Zacks Investment Research
Biodexa Pharmaceuticals (BDRX) Short Interest & Short Float | Updated Mar 2026 - MarketBeat
Lipella Pharmaceuticals (LIPO) Short Interest & Short Float | Updated Feb 2026 $LIPO - MarketBeat
Scinai Immunotherapeutics Ltd Adr (SCNI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):